tbuckley/cabot-search huggingface dataset:
Juul shipped a million contaminated e-cigarette pods, claims lawsuit from former employee
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The US electronic cigarette company Juul has been accused of shipping one million contaminated e-cigarette nicotine pods, in a lawsuit filed by a former employee.

Siddharth Breja, who was the company’s senior vice president for finance until March 2019, has claimed that his employment was unlawfully terminated in “retaliation for whistleblowing and objecting to the contaminated pod shipment and other illegal and unsafe conduct that has jeopardized and continues to jeopardize public health and safety and the lives of millions of consumers, many of them children and teens.”

The lawsuit, filed on 29 October at the US District Court of the Northern District of California, outlines the situations in which Breja said he raised concerns about decisions allegedly made by senior members of staff.

These, Breja alleges, included intentions to ship expired or nearly expired products, refusing to put expiration dates on products, and a proposal to trick EU regulators so that the company could sell a product that would exceed nicotine concentration …
Self-Reported Changes in the Expanded Disability Status Scale (EDSS) Score in Persons with Multiple Sclerosis after Autologous Stem Cell Transplants: Experience with the "Mexican Method"
Authors: Guillermo J. Ruiz-Arguelles, Juan Carlos Olivares-Gazca, Iván Murrieta-Álvarez, Jesús Mauricio Olivares-Gazca, Andres Leon-Peña, Yahveth Cantero-Fortiz, Elías Eugenio Gonzalez López, Alejandro Ruiz-Argüelles, Andres Gomez De Leon, David Gomez-Almaguer, Luisa Fernanda Sánchez-Valledor, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Guillermo J. Ruiz-Delgado
Journal: Blood (2019)
Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group
Authors: Vassiliki Mpakou, Aris Spathis, Anthi Bouhla, Frieda Kontsioti, Zoi Tsakiraki, Sotirios Papageorgiou, Efthimia Mpazani, Irene Glezou, Konstantinos Gkodopoulos, Georgia Stavroulaki, Athanasios Galanopoulos, Argiris Symeonidis, Nora-Athina Viniou, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, Periklis Foukas, Vassiliki Pappa
Journal: Blood (2019)
Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population
Authors: Urshila Durani, Dennis Asante, Thorvardur Halfdanarson, Herbert C. Heien, Lindsey Sangaralingham, Carrie A. Thompson, Prema Peethambaram, Fernando J. Quevedo, Ronald S. Go
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Adherence to surveillance guidelines in resected colon cancer has significant implications for patient morbidity, cost of care, and healthcare utilization. This study measured the underuse and overuse of imaging for staging and surveillance in stage I–II colon cancer. Methods: The OptumLabs database was queried for administrative claims data on adult patients with stage I–II colon cancer who underwent surgery alone in 2008 through 2016. Use of PET and CT imaging was evaluated during both initial staging (n=6,921) and surveillance for patients with at least 1 year of follow-up (n=5,466). “High use” was defined as &gt;2 CT abdominal/pelvic (CT A/P) or PET scans per year during surveillance. Results: Overall, 27% of patients with stage I–II colon cancer did not have a staging CT A/P or PET scan and 95% did not have a CT chest scan. However, rates of staging CT A/P and CT chest scans increased from 62.0% (2008) to 74.8% (2016) and from 2.3% (2008) to 7.1% (2016), respectively. Staging PET use was overall very low (5.2%). During surveillance, approximately 30% of patients received a CT A/P or PET and 5% received a CT chest scan within the first year after surgery. Of patients who had surveillance CT A/P or PET scans, the proportion receiving &gt;2 scans within the first year (high use) declined from 32.4% (2008) to 9.6% (2016) ( P = .01). Conclusions: Although PET use remains appropriately low, many patients with stage I–II colon cancer do not receive appropriate staging and surveillance CT chest scans. Among those who do receive these scans during surveillance, high use has declined significantly over time.
Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)
Authors: Yaya Chu, Julie-An Talano, Lee Ann Baxter-Lowe, Carolyn A. Keever-Taylor, Erin Morris, Harshini Mahanti, Janet Ayello, Rona Singer Weinberg, Qiuhu Shi, Theodore B. Moore, Sandra Fabricatore, Brenda J. Grossman, Carmella van de Ven, Shalini Shenoy, Mitchell S Cairo
Journal: Blood (2019)
Epicardial Adipose Tissue
Authors: Samia Massalha, Jeroen Walpot, Damini Dey, Emel Celiker Guler, Owen Clarkin, Laura Godkin, Indeevari Ratnayake, Pranisha Jayasinghe, Alomgir Hossain, Andrew Crean, Matthew Chan, Craig Butler, Vikas Tandon, Peter Nagele, Pamela K. Woodard, Marko Mrkobrada, Wojciech Szczeklik, Yang Faridah Abdul Aziz, Bruce Biccard, P.J. Devereaux, Tej Sheth, Benjamin J.W. Chow
Journal: JACC. Cardiovascular imaging (2019)
Planning and World Population
Authors: G. Macdonald
Journal: BMJ (1947)

America's numerous centres of clinical research it was interesting to see that, although it is only three months since the A.M.A. meeting, a large proportion of these exhi- bits were on original and unpublished work.As was to be expected, many of the papers in the gastric surgery forum were on various aspects of vagotomy, both in the human subject and in experimental animals.In the cardiovascular surgical forum there were several papers on portacaval anastomosis, one on a new operation for left coronary throm- bosis and sclerosis, and another on experimental methods of aortic valvulotomy.In other sections there were papers on the evaluation of streptomycin in intestinal strangulation and as a pre-operative medicament for abdominal surgery, and studies on its influence on post-operative healing of the bowel.The role of isotopes in biological research was also discussed, and economic details and an account of the liaison between the research worker and the physicist were given.The twenty-sixth Annual Hospital Standardization Cqverence was held in conjunction with the surgical conference.7 Papers and discussions ranged from problems in hospital man4awment and finance, through technical aspects of labour and stai'"ilng,
STEM-08. GENE THERAPY USING IL-24-EXPRESSING UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS AGAINST GLIOMA
Authors: Shaochen Fan, Yilu Gao
Journal: Neuro-Oncology (2019)

Abstract Despite many advances have been made in treatment of gliomas, patients prognosis remains poor. Stem cell-based therapy has been thought to be a promising option for gliomas and many studies have reported that umbilical cord-derived mesenchymal stem cells (UC-MSCs) are ideal gene vectors for tumor gene therapy. Interleukin 24 (IL-24) is a pleiotropic immunoregulatory cytokine which has an apoptotic effect on many kinds of tumor cells and can inhibit the growth of tumors specifically without damaging normal cells. However, there are still some challenges in its clinical application, such as the half-life, toxicity caused by high-dose application, and so on. Therefore, we hypothesize that combination of gene transfer with stem cell transplantation could overcome the problems. In this study, we investigated UC-MSCs transduced with lentiviral vectors carrying IL-24 complementary DNA as a vehicle for the targeted delivery of IL-24 to local tumor sites. The engineered UC-MSCs selectively migrated to glioma cells and showed the antitumor effect in vitro and in vivo. The restrictive efficacy of these UC-MSCs was related to the inhibition of proliferation and induction of apoptosis in tumor cells. These findings indicate that UC-MSCs-based IL-24 gene therapy can obviously suppress the growth of glioma xenografts, thereby suggesting the potential for future therapeutic interventions in the treatment of gliomas. Keywords: Glioma, Gene therapy, Umbilical cord-derived mesenchymal stem cells (UC-MSCs), Interleukin 24 (IL-24)
Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies
Authors: Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, Pierre I. Karakiewicz
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Use of inpatient palliative care (IPC) in the treatment of advanced cancer represents a well-established guideline recommendation. A recent analysis showed that patients with genitourinary cancer benefit from IPC at the second lowest rate among 4 examined primary cancers, namely lung, breast, colorectal, and genitourinary. Based on this observation, temporal trends and predictors of IPC use were examined in patients with metastatic urothelial carcinoma of the bladder (mUCB) receiving critical care therapies (CCTs). Patients and Methods: Patients with mUCB receiving CCTs were identified within the Nationwide Inpatient Sample database (2004–2015). IPC use rates were evaluated in estimated annual percentage change (EAPC) analyses. Multivariable logistic regression models with adjustment for clustering at the hospital level were used. Results: Of 1,944 patients with mUCB receiving CCTs, 191 (9.8%) received IPC. From 2004 through 2015, IPC use increased from 0.7% to 25.0%, respectively (EAPC, +23.9%; P &lt;.001). In analyses stratified according to regions, the highest increase in IPC use was recorded in the Northeast (EAPC, +44.0%), followed by the West (EAPC, +26.8%), South (EAPC, +22.9%), and Midwest (EAPC, +15.5%). Moreover, the lowest rate of IPC adoption in 2015 was recorded in the Midwest (14.3%). In multivariable logistic regression models, teaching status (odds ratio [OR], 1.97; P &lt;.001), more recent diagnosis (2010–2015; OR, 3.89; P &lt;.001), and presence of liver metastases (OR, 1.77; P =.02) were associated with higher IPC rates. Conversely, Hispanic race (OR, 0.42; P =.03) and being hospitalized in the Northeast (OR, 0.36; P =.01) were associated with lower rate of IPC adoption. Finally, patients with a primary admission diagnosis that consisted of infection (OR, 2.05; P =.002), cardiovascular disorders (OR, 2.10; P =.03), or pulmonary disorders (OR, 2.81; P =.005) were more likely to receive IPC. Conclusions: The rate of IPC use in patients with mUCB receiving CCTs sharply increased between 2004 and 2015. The presence of liver metastases, infections, or cardiopulmonary disorders as admission diagnoses represented independent predictors of higher IPC use. Conversely, Hispanic race, nonteaching hospital status, and hospitalization in the Midwest were identified as independent predictors of lower IPC use and represent targets for efforts to improve IPC delivery in patients with mUCB receiving CCT.
Resequencing of 414 cultivated and wild watermelon accessions identifies selection for fruit quality traits
Authors: Shaogui Guo, Shengjie Zhao, Honghe Sun, Xin Wang, Shan Wu, Tao Lin, Yi Ren, Lei Gao, Yun Deng, Jie Zhang, Xuqiang Lu, Haiying Zhang, Jianli Shang, Guoyi Gong, Changlong Wen, Nan He, Shouwei Tian, Maoying Li, Junpu Liu, Yanping Wang, Yingchun Zhu, Robert Jarret, Amnon Levi, Xingping Zhang, Sanwen Huang, Zhangjun Fei, Wenge Liu, Yong Xu
Journal: Nature Genetics (2019)

Fruit characteristics of sweet watermelon are largely the result of human selection. Here we report an improved watermelon reference genome and whole-genome resequencing of 414 accessions representing all extant species in the Citrullus genus. Population genomic analyses reveal the evolutionary history of Citrullus, suggesting independent evolutions in Citrullus amarus and the lineage containing Citrullus lanatus and Citrullus mucosospermus. Our findings indicate that different loci affecting watermelon fruit size have been under selection during speciation, domestication and improvement. A non-bitter allele, arising in the progenitor of sweet watermelon, is largely fixed in C. lanatus. Selection for flesh sweetness started in the progenitor of C. lanatus and continues through modern breeding on loci controlling raffinose catabolism and sugar transport. Fruit flesh coloration and sugar accumulation might have co-evolved through shared genetic components including a sugar transporter gene. This study provides valuable genomic resources and sheds light on watermelon speciation and breeding history.
Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib
Authors: Moshe Yair Levy, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Jing Xu, Qisu Zhang, Mehul Dalal
Journal: Blood (2019)
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Authors: Teodora Kuzmanovic, Bhumika J. Patel, Jibran Durrani, Hassan Awada, Cassandra M Kerr, Bartlomiej P. Przychodzen, Samuel Li, Seth J. Corey, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Thomas Laframboise, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2019)
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
Authors: William B. Donnellan, Ehab L. Atallah, Adam S. Asch, Manish R. Patel, Jay Yang, Alireza Eghtedar, Gautam M. Borthakur, Julie Charlton, Alexander MacDonald, Anna Korzeniowska, Elizabeth Sainsbury, Donald K. Strickland, Suzanne Jones, Philip Overend, Carrie A. Adelman, Giulia Fabbri, Jon Travers, Simon Smith, J. Elizabeth Pease, Jan Cosaert
Journal: Blood (2019)
Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial
Authors: Uwe Platzbecker, Diana Dunshee, Rami S. Komrokji, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein, Valeria Santini, María Díez-Campelo, Mikkael A. Sekeres, Wendy L. See, Kevin Tsai, Alberto Risueño, Jianglin Ma, Martin Schwickart, Anita Rampersad, Jennie Zhang, Abderrahmane Laadem, Daniel Menezes, Kyle MacBeth, Peter G. Linde, Joseph G. Reynolds, Alan F. List, Pierre Fenaux
Journal: Blood (2019)
Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Authors: Scott R. Solomon, Melhem Solh, Stacey Brown, Katelin C Jackson, Xu Zhang, Lawrence E Morris, H. Kent Holland, Asad Bashey
Journal: Blood (2019)
Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts
Authors: Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, Sutapa Sinha, Raphael Mwangi, Nancy Scott, Mehrdad Hefazi, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, Michael W. Ruff, Sameer A. Parikh, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2019)
Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure
Authors: Nadim Mahmud, Vinay Sundaram, David E. Kaplan, Tamar H. Taddei, David S. Goldberg
Journal: Hepatology (2019)

Background and Aims Acute on chronic liver failure (ACLF) results in extremely high short‐term mortality in patients with underlying cirrhosis. The European Association for the Study of the Liver criteria grade ACLF severity from 1 (least severe) to 3 (most severe) based on organ failures (OFs) that develop after an acute decompensation (AD). However, the implications of surviving low‐grade ACLF in terms of risk of subsequent high‐grade ACLF are unclear. Approach and Results We conducted a retrospective cohort study of patients with compensated cirrhosis in the Veterans Health Administration database from January 2008 to June 2016. Propensity matching for grade 1 (G1) ACLF, followed by Cox regression, was used to model risk of subsequent grade 3 (G3) ACLF. Stratified analyses of different ADs and OFs were also performed. We identified 4,878 patients with well‐matched propensity scores. G1 ACLF events conferred a significantly increased risk of subsequent G3 ACLF relative no previous G1 ACLF (hazard ratio, 8.69; P &lt; 0.001). When stratified by AD, patients with ascites or hepatic encephalopathy were significantly more likely to develop G3 ACLF relative to those with gastrointestinal bleed or infection as an AD ( P &lt; 0.001). Risk of G3 ACLF also varied significantly by type of OF characterizing previous G1 ACLF, with liver, coagulation, and circulatory failure posing the highest increased risk. Conclusions Patients who recover from G1 ACLF have substantially increased risk of later developing G3 ACLF as compared to those who never have G1 ACLF. Moreover, reversible decompensations for G1 ACLF have a lower risk of G3 ACLF, and liver‐intrinsic OFs confer a much higher risk of G3 ACLF. These findings have implications for prognosis, future surveillance, and triaging early transplant evaluation.
Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts
Authors: Seung Jun Shin, Elissa B. Dodd-Eaton, Gang Peng, Jasmina Bojadzieva, Jingxiao Chen, Christopher I. Amos, Megan N. Frone, Payal P. Khincha, Phuong L. Mai, Sharon A. Savage, Mandy L. Ballinger, David M. Thomas, Ying Yuan, Louise C. Strong, Wenyi Wang
Journal: Cancer Research (2019)

Abstract Li-Fraumeni syndrome (LFS) is a rare hereditary cancer syndrome associated with an autosomal-dominant mutation inheritance in the TP53 tumor suppressor gene and a wide spectrum of cancer diagnoses. The previously developed R package, LFSPRO, is capable of estimating the risk of an individual being a TP53 mutation carrier. However, an accurate estimation of the penetrance of different cancer types in LFS is crucial to improve the clinical characterization and management of high-risk individuals. Here, we developed a competing risk-based statistical model that incorporates the pedigree structure efficiently into the penetrance estimation and corrects for ascertainment bias while also increasing the effective sample size of this rare population. This enabled successful estimation of TP53 penetrance for three LFS cancer types: breast (BR), sarcoma (SA), and others (OT), from 186 pediatric sarcoma families collected at MD Anderson Cancer Center (Houston, TX). Penetrance validation was performed on a combined dataset of two clinically ascertained family cohorts with cancer to overcome internal bias in each (total number of families = 668). The age-dependent onset probability distributions of specific cancer types were different. For breast cancer, the TP53 penetrance went up at an earlier age than the reported BRCA1/2 penetrance. The prediction performance of the penetrance estimates was validated by the combined independent cohorts (BR = 85, SA = 540, and OT = 158). Area under the ROC curves (AUC) were 0.92 (BR), 0.75 (SA), and 0.81 (OT). The new penetrance estimates have been incorporated into the current LFSPRO R package to provide risk estimates for the diagnosis of breast cancer, sarcoma, or other cancers. Significance: These findings provide specific penetrance estimates for LFS-associated cancers, which will likely impact the management of families at high risk of LFS. See related article by Shin et al., p. 347
Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials
Authors: Thura Win Htut, Kyaw Zin Thein, Anita Sultan, Sriman Swarup, Myint Aung Win, Ei Moe Phyu, Sanjay Awasthi, Akshar Dash, Myat Min Han, Yin Mon Myat, Fred Hardwicke, Lukman Tijani, Nicholas D'Cunha, Donald P. Quick
Journal: Blood (2019)
Breast or bottle.
Authors: H Graham
Journal: BMJ (1979)

In our survey2 we found in the five types of schools where a cold buffet was offered that the average food per plate provided 10-25 IO less than the hot meal in the same school both for energy and for protein.At that time we were considering whether or not the target was being achieved and this greater shortfall with the cold buffet indicated that it was not getting as near the target as was the hot meal.However, since children vary so much in their needs perhaps, when offered a choice, they select what they need rather than what the nutritionist thinks that, on average, they ought to have.On this basis there might be an actual saving in the cost of food if the children were offered a choice instead of the traditional approach.Cerainly sandwiches, beans on toast, and similar snacks which are usually looked down on can be as nutritious as a traditional hot meal.
GATA2-Dependent Developmental and Regenerative Networks
Authors: Alexandra Soukup, Kirby D Johnson, Daniel J Conn, Evgenia Shishkova, Koichi Ricardo Katsumura, Peng Liu, Erik A. Ranheim, Katherine R. Calvo, Amy P. Hsu, Steven M. Holland, Joshua J Coon, Sunduz Keles, Emery H Bresnick
Journal: Blood (2019)
A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress
Authors: Xie-an Yu, Mi Lu, Yingping Luo, Yiting Hu, Ying Zhang, Zhiming Xu, Shuaishuai Gong, Yunhao Wu, Xiao-Nan Ma, Bo-Yang Yu, Jiangwei Tian
Journal: Theranostics (2019)

Rationale: Despite considerable advances, the reactive oxygen species (ROS)-mediated cancer treatment suffers from the problems of up-regulation of adaptive antioxidants in cancer cells as well as side effects to normal cells. Therefore, development of a new generation of cancer-specific nanomedicine capable of amplifying oxidative stress would be of great interest for accurate and effective cancer treatment. Methods: Herein, transferrin (Tf)-decorated, dihydroartemisinin (DHA), L-buthionine-sulfoximine (BSO), and CellROX-loaded liposomal nanoparticles (Tf-DBC NPs) were developed for precise cancer theranositcs. Tf-DBC NPs could specifically recognize cancer cells via Tf-Tf receptor binding and be uptaken into the lysosomes of cancer cells, where Tf-DBC NPs were activated to release Fe(II), DHA, and BSO. ROS was generated by DHA in the presence of Fe(II), and GSH was depleted by BSO to disrupt the redox balance in cancer cells. Furthermore, CellROX, as a fluorescent probe for imaging of intracellular oxidative stress, was used to monitor the therapeutic efficacy. Results: The integration of Tf, DHA, and BSO into the acidic pH-responsive liposomes selectively and effectively killed cancer cells and prevented the oxidative injury to normal cells. The high oxidative state was visualized at the tumor site and the amplification of oxidative stress enabled tumor eradication by Tf-DBC NPs, demonstrating the successful implementation of this novel strategy in vivo. Conclusion: Our study provides a new paradigm for the design of ROS-mediated therapeutics and offers a promising perspective for precise cancer treatment.
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease
Authors: Derek Klarin, Emma Busenkell, Renae Judy, Julie Lynch, Michael Levin, Jeffery Haessler, Krishna Aragam, Mark Chaffin, Mary Haas, Sara Lindström, Themistocles L. Assimes, Jie Huang, Kyung Min Lee, Qing Shao, Jennifer E. Huffman, Christopher Kabrhel, Yunfeng Huang, Yan V. Sun, Marijana Vujkovic, Danish Saleheen, Donald R. Miller, Peter Reaven, Scott DuVall, William E. Boden, Saiju Pyarajan, Alex P. Reiner, David-Alexandre Trégouët, Peter Henke, Charles Kooperberg, J. Michael Gaziano, John Concato, Daniel J. Rader, Kelly Cho, Kyong-Mi Chang, Peter W. F. Wilson, Nicholas L. Smith, Christopher J. O’Donnell, Philip S. Tsao, Sekar Kathiresan, Andrea Obi, Scott M. Damrauer, Pradeep Natarajan
Journal: Nature Genetics (2019)